When the Consumable Is the Method: How NAMs Are Starting to Reshape 3D Culture Supply

How FDA qualification, OECD guidelines, and supplier pairings are tying plates, chips, matrices, and media to defined methods

Key Takeaways

• In September 2026, Emulate submitted its full Human Liver-Chip qualification package to the FDA’s ISTAND program, and Molecular Devices and STEMCELL Technologies announced a validated automated workflow for IntestiCult Plus organoid medium on the CellXpress.ai system.
• The FDA’s March 2026 draft guidance on NAMs asks developers to document cell sources and batch numbers, show that results hold as new batches are resupplied, and rule out absorption of the test compound in culture wells.
• Matrices and plastics can change assay outcomes. BME varies from lot to lot, and binding to plastic or partitioning into PDMS can leave less free drug than the nominal dose suggests.
• OECD skin model guidelines show that being named in a method brings obligations as well as demand, as the EpiSkin removal in December 2024 illustrates.
• FDA qualification carries no industry-wide deadline like the EU’s cosmetics ban, so a qualified chip would gain users program by program.
• Near-term 3D culture demand depends more on research budgets than regulation. SDi expects 2026 to be the softest year of its forecast, with applied R&D and CRO analytical services growing faster than basic research through 2030.

In September 2026, two announcements tied a specific 3D culture consumable to a defined method, one through FDA qualification and the other through validation on an automated culture system. On September 9, Emulate announced that it had submitted the full qualification package for its Human Liver-Chip, for assessing drug-induced liver injury, to the FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) program, which the agency made permanent in July 2025. Five days later, Molecular Devices and STEMCELL Technologies announced a validated automated workflow for STEMCELL’s IntestiCult Plus organoid medium on Molecular Devices’ CellXpress.ai culture system.

Both announcements reflect how 3D culture works: the plate, chip, matrix, and medium change what a model does, so a result depends on which ones were used. The FDA’s March 2026 draft guidance on new approach methodologies (NAMs) asks drug developers to document cell sources and batch numbers, show that results hold as new batches of cells and reagents are resupplied, and rule out absorption of the test compound in culture wells. For platforms such as organ chips, it also asks developers to characterize scaffolds and matrices.

In SDi’s new Market Opportunity for 3D Cell Culture report, forecasts differ by end use and by how easily a product can be replaced. Chip consumables are expected to grow faster than the rest of 3D plasticware, driven by pharma safety adoption and FDA qualification activity. Ultra-low attachment plates face competition from many smaller suppliers and from in-house methods. Organoid media and supplements, used in R&D and in lab-developed tests (LDTs), are expected to grow faster than other 3D culture reagents. In August 2026, China made one such test, tumor organoid drug-sensitivity testing, a billable hospital service.

Consumables Shape Assay Outcomes

Most organoids are still grown in basement membrane extract (BME), a gel taken from a mouse sarcoma. Its protein and residual growth-factor content varies from lot to lot, which can change how organoids grow, differentiate, and respond to drugs. The gel’s mouse tumor origin also raises questions for cancer and immune research: it exposes human cells to mouse proteins, which may trigger immune reactions, a concern when human immune cells are added to the culture.

In a 2024 JCI Insight study of pancreatic cancer organoids, dose-response curves were largely similar across Matrigel, Cultrex, and UltiMatrix, with some drug-specific differences, but the organoids grew faster in Matrigel, and the authors recommended keeping the BME source constant for drug testing. In high-throughput screens, that need for consistency helps sustain the commercial matrix market, even though some labs continue to make or extract their own collagen. Bio-Techne launched a fully defined Cultrex Synthetic Hydrogel in February 2026, citing lot-to-lot variability; many other suppliers offer alternative matrices.

Plastics in plates and chips can also change the dose. For some compounds, binding to plastic and serum proteins, or partitioning into PDMS (the silicone used in many organ chips) leaves less free drug in a well than the nominal dose suggests. Several organ-chip makers, including CN Bio and MIMETAS, market PDMS-free plates to limit that loss.

Suppliers Are Pairing Consumables With Defined Methods

Several suppliers now sell consumables together with the instruments, protocols, or services that use them. The Molecular Devices and STEMCELL workflow is the first milestone in a broader collaboration to automate STEMCELL’s organoid kits, and in August Molecular Devices and HeartBeat.bio announced a cardiac organoid supplement kit designed for manual or automated use. InSphero agreed in November 2025 to acquire DOPPL, including the Gri3D microwell plates for producing organoids, and built its gastrointestinal toxicity screen on those plates. In May 2026, it bought PhenoVista, a CRO specializing in imaging-based assays.

Emulate’s package is the only one of these aimed at FDA qualification. The Liver-Chip entered ISTAND in 2024 as the Liver-Chip S1, with initial data generated on Emulate’s Zoë instrument, and the final package adds data from AVA, Emulate’s 96-chip system, which uses a different chip format. According to Emulate, the package shows reproducibility across three independent laboratories using three different primary human hepatocyte donors.

If the FDA qualifies the chip, any drug developer could use it for the same purpose, its “context of use,” without the FDA generally having to re-review whether it is suitable. Qualification is not exclusive, and not limited to chips: the FDA has also accepted an in silico model for predicting drug-induced liver injury into ISTAND. The law behind the program also lets the FDA modify or rescind a qualification if a tool proves unsuitable for its context of use.

What Skin Models Show

Reconstructed skin models illustrate what happens when consumables become part of a regulatory method. The Organisation for Economic Co-operation and Development (OECD), an intergovernmental organization of 38 member countries, does not regulate products. It publishes Test Guidelines that national regulators apply. Under its Mutual Acceptance of Data system, data produced with those guidelines in labs following OECD Good Laboratory Practice must be accepted in every participating country. Test Guideline 439, for skin irritation, names its accepted methods after commercial models, including MatTek’s EpiDerm, EPISKIN’s SkinEthic, South Korea’s KeraSkin, and Japan’s LabCyte. A 2016 study noted that every validated method then relied on models from only three companies.

Being named has brought obligations as well as demand. A modified version of EpiDerm had to be validated again in 2008. When EpiSkin went off the market in December 2024, the OECD revised its skin irritation and skin corrosion guidelines to remove it, and South Korea made the same change to its national skin irritation guideline. In September 2025, Fraunhofer took over Henkel’s epiCS model and described the move as keeping epiCS available for OECD 439 testing.

Demand for these models also had a mandate behind it. Purchases of commercial reconstructed tissues are weighted toward Europe because of the EU’s ban on marketing animal-tested cosmetics, fully in effect since March 2013, and REACH, which allows vertebrate testing only as a last resort. In Asia, China’s acceptance of in vitro methods for cosmetics adds demand. The OECD itself requires no one to use these models, and REACH can still require animal tests where alternatives are judged insufficient, for example to protect workers exposed to a chemical.

FDA qualification comes with no such mandate; a qualified chip will gain users as individual drug developers choose it over animal studies and in-house models, program by program, rather than through an industry-wide deadline like the EU’s. The FDA Modernization Act 2.0 of 2022 removed the statutory requirement for animal testing without requiring alternatives. The FDA’s September 21 direct final rule replaces “animal” with “nonclinical” in several drug and biologics regulations, effective February 4, 2027, but it still does not prohibit animal studies.

Outlook

SDi’s Market Opportunity for 3D Cell Culture report sizes the market for 3D culture reagents, ready-made models, and 3D plasticware through 2030 by product type, end market, region, and lab function, with pricing, unit volumes, and supplier shares. Near-term demand depends more on research budgets than on regulation. Most 3D culture spending comes from basic and applied R&D; regulated testing is a minor share. We expect 2026 to be the softest year of our forecast because of weak US academic purchasing, but forecast applied R&D and CRO analytical services to grow faster than basic research through 2030.

For suppliers, documentation separates consumables tied to a defined method from interchangeable ones. Matrix, media, and chip suppliers are likely to field requests from pharma and CRO customers for lot-level characterization, lot-to-lot comparison data, compound-binding data, and advance notice of changes. Those whose products enter qualified or guideline-listed methods may face questions similar to those skin-model makers have faced.

Major scientific tools companies have bought, or agreed to buy, makers of models, chips, and matrices. Bruker announced a majority investment in organ-chip developer MIMETAS in August 2026, Sartorius bought MatTek in 2025, and Merck KGaA’s pending acquisition of Bio-Techne, announced in June as a multi-omics, spatial biology, and cell and gene therapy deal, would bring Cultrex matrices and R&D Systems growth factors under MilliporeSigma.

Standardization work could formalize some of these documentation expectations. The NIH established a Standardized Organoid Modeling Center in September 2025, and ISO is drafting organoid standards that cover manufacturing and quality control. The FDA’s decision on the Liver-Chip will show whether an organ chip can hold the kind of named position skin models hold under OECD Test Guidelines.

Want the numbers behind this analysis?

SDi’s Market Opportunity for 3D Cell Culture & NAMs 2026 covers three consumables segments: 3D plasticware, 3D culture reagents, and ready-made 3D models. Demand is segmented by product type, sector, end market, region, function, and application, with five-year forecasts and vendor market shares.

Frequently Asked Questions